Cytodyn Inc

OTCQB:CYDYUnited States

CytoDyn Inc. is a clinical-stage biotechnology company that is focused on developing treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. Its clinical developments include human immunodeficiency virus (HIV), nonalcoholic steatohepatis (NASH) and solid tumors in oncology. In HIV, it focuses on the multi-drug resistant HIV population, creating a long-acting formulation of leronlimab, and HIV cure using adenovirus vectors. Its NASH focuses on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Its oncology product focuses on the combination therapy for solid tumors to explore the potential of leronlimab in the tumor microenvironment and the potential benefit for decreasing angiogenesis, potential macrophage repolarization, decreasing metastasis.

Contact Information

Headquarters

1111 Main St Ste 660VANCOUVER, WA, United States 98660-2970

Phone

360-980-8524

Fax

302-655-5049

Executives

Chairman of the Board

Tanya Urbach

President

Cyrus Arman

Interim President, Chief Financial Officer, Vice President, Controller, Treasurer

Antonio Migliarese

Executive Director - CMC Regulatory Affairs

Seenu Srinivasan

Director

Karen Brunke